Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANI Ready For Full-Scale Commercial Launch Of FDA-Approved Cortrophin Gel

Company’s Acquisition Of Novitium To Close This Month

Executive Summary

ANI Pharmaceuticals has announced receiving the long-awaited FDA approval for its Cortrophin Gel and has plans for a full-scale commercial launch of the product in the first quarter of 2022. Meanwhile, ANI’s $210m acquisition of niche generics specialist Novitium Pharma is expected to close imminently.

You may also be interested in...



ANI Pharmaceuticals Completes $210m Novitium Acquisition

ANI Pharmaceuticals has completed its acquisition of niche generics specialist Novitium Pharma, securing access to a pipeline of generics and 505(b)(2) candidates that has expanded further since the deal was announced earlier in the year.

ANI Picks Up US Dermatology Brands From Sandoz

ANI Pharmaceuticals has added to its branded portfolio by acquiring several dermatology brands from Sandoz in the US.

ANI Snaps Up Novitium In Deal Worth Up To $210m

ANI Pharmaceuticals has struck a deal worth up to $210m to acquire niche generics specialist Novitium Pharma, a move that the firm says will bring it a healthy pipeline of ANDAs and 505(b)(2) products as well as enhancing its CDMO business.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel